Estrogen Patch Shortages Persist as Demand Surges

Prescriptions for these patches have surged 162% over the last two years, driven by a cultural shift in how menopause is discussed and a pivotal regulatory change. Last fall, the Food and Drug Administration removed a decades-old black box warning that had long discouraged the use of hormone replacement therapy. The agency acknowledged that initial 2002 research linking estrogen to increased risks of breast cancer and dementia had overstated the dangers for the average woman starting treatment.

This policy reversal, coupled with advocacy from celebrities and social media communities, has sent demand to unprecedented levels. Data from HealthVerity shows that patch prescriptions jumped from roughly 594,000 in June 2022 to 1.6 million by May 2024. Despite this, manufacturers are struggling to scale production, with the American Society of Health-System Pharmacists reporting shortages across three types of patches.

For patients, the scarcity is more than a logistical nuisance. Doctors like Dr. Susan Loeb-Zeitlin of Weill Cornell Medicine emphasize that topical patches are preferred over oral alternatives for their safety profile. As telehealth providers like Hers report a tripling of interest in their menopause programs since October, the gap between availability and clinical need remains wide. Industry analysts suggest it could take at least a year for supply chains to stabilize, leaving women and their healthcare providers to navigate a fragmented market in the interim.